after percutaneous insertion of a subclavian central venous catheter from pneumothorax and hemorrhage. Two patients suffered cardiac arrest with pulseless electrical activity: one from an anaphylactic reaction to plasma and the other from pericardial hemorrhage and tamponade, presumably due to cardiac perforation by an internal jugular catheter insertion guidewire.
Other major catheter-related complications included one patient with a retroperitoneal hemorrhage following femoral catheter insertion and seven patients with catheter thrombosis that prevented PE and/or required placement of a new central venous catheter; two of these seven patients had catheter-related venous thrombosis requiring systemic anticoagulation. Ten patients developed systemic infection: eight had blood cultures positive for the presence of bacteria (Staphylococcus aureus [five] , Staphylococcus epidermidis [three] ); the two patients with negative blood cultures were treated with parenteral antibiotics for presumed sepsis.
Other major plasma-related complications included hypotension in two patients requiring dopamine, acute hypoxia in two patients, serum sickness in one patient requiring systemic glucocorticoids, and severe vomiting in one patient that prevented completion of PE.
Twenty-seven (35 percent) patients developed minor complications, including 10 patients who also had major complications. The majority of the minor complications were urticaria (22 patients); other minor complications included vomiting, tetany, and hypotension responding to intravenous fluids.
These data confirm and extend our previous report. 3 and to monitor chimerism after marrow transplantation. 4, 5 We report the case of a woman whose fetus died in utero at 35 weeks of gestation following trauma. The woman's RBCs were Group A, D+, and the antibody screen was negative. The Kleihauer-Betke test demonstrated a 50-mL FMH. Cord blood was not available for phenotyping. It was therefore not known whether she could be immunized to antigens (other than D) expressed on fetal RBCs. Fetal and maternal RBCs were phenotyped by flow cytometry, the large FMH was confirmed, and an antigen mismatch was identified.
RBCs from the patient, two adult donors (controls, phenotypes O R 1 R 2 and O rr K+ k+ Fy(a+b+) JK(a+b+)), and cord blood were washed, and a mixture of cord and adult RBCs was made; 20-L aliquots of 5 percent suspensions were labeled with 10 L of FITC-conjugated anti-HbF (Silenus, Boronia, Victoria, Australia), (Table 1) . RBCs were incubated either at room temperature for 30 minutes (anti-HbF) or at 37ЊC for 1 hour (blood group antibodies). Before labeling with anti-HbF, RBCs were fixed (in 1 mL of 0.05 percent glutaraldehyde in PBS), washed, permeabilized (in 0.5 mL of 0.1% Triton X-100 in PBS with 0.1% BSA), and washed. 1 Unlabeled primary antibodies were detected with 100 L of 1-in-100 FITC-conjugated anti-human IgG (F(ab); Jackson ImmunoResearch, West Grove, PA). Samples were analyzed with a flow cytometer (FACSCalibur, Becton Dickinson, Oxford, UK), 6 collecting 50,000 events and placing markers as appropriate on histograms of logintegrated FL1 fluorescence. The percentage of gated events and the median fluorescence of events under the markers were computed.
Using adult RBCs alone or with added cord RBCs, a marker was set to encompass strongly fluorescent fetal RBCs on histograms of FITC-anti-HbF-stained RBCs. The percentage of events under this marker in the adult sample (0.09%) was subtracted from that of the patient's sample (2.59%), that is, 2.5 percent (Fig. 1A) . Using the formula FMH (mL of packed fetal RBCs) = percentage of positive events ‫ן‬ 22, 6 the FMH in the patient's sample was calculated to be 55 mL.
The median fluorescence of RBCs obtained with the blood group-specific antibodies is listed in Table 1 (Fig. 1B) . Subtracting the background of unlabeled events under this marker (0.2%) gave 2 percent K-cells or a 44-mL FMH.
Some examples of anti-C, anti-c, and anti-E gave greater fluorescence than others (Table 1) . It was ob- served previously that some IgG non-anti-D MoAbs gave relatively low fluorescence in flow cytometry, compared to agglutination. 7 IgM antibodies against Rh C, c, E, and e may be more effective. 5 On the basis of the median fluorescence values, the most likely phenotypes of maternal and fetal RBCs in the patient's sample were maternal, C+ , c+ , D+ , E+ , K+ , k+, Fy(a+b+), Jk(a+ b-); and fetal, C+ , c+ , D+ , E+ , K-, k+, Fy(a+b+), Jk(a+b-). The only difference detected between maternal and fetal RBCs was that fetal RBCs were K-. Thus, using this panel of antibodies, there were no blood group antigens detected on fetal RBCs that could immunize the mother.
Flow cytometry can reliably detect minor RBC populations of 1 percent or less, depending on the antibody used for identification, and has advantages over other techniques such as differential agglutination 8, 9 (rapid but less sensitive) and microscopic enumeration of RBCbinding fluorescent microspheres 10 (sensitive but tedious). Reports of flow cytometric detection and quantitation of minor cell populations when using one to three antibodies have been extensively reviewed. 11 The case study detailed here demonstrates the utility and rapidity of flow cytometry, both for quantitation of FMH and for extensive phenotyping of mixed RBC populations. 
Ten-year survival of transfusion recipients identified by hepatitis C lookback
Empirical data from population-based studies on the long-term (Ն10-year posttransfusion) probability of survival of transfusion recipients are needed for public policy decisions, 1 but no such data currently exist for patients transfused after 1981. The 10-year probabilities of survival of Olmsted County, Minnesota residents transfused in 1981 2 were often used previously, but these figures most likely do not reflect the survival of patients transfused in the 1990s. Five-to 10-year posttransfusion probabilities of survival that range from 26 3 to 41 percent 4 can be inferred from HCV lookback studies. 1 These studies were not designed to calculate posttransfusion survival, however, and it is difficult to infer the length of recipient follow-up from the presented data. 1, 5 The New York University Medical Center (NYUMC) HCV lookback study was designed to calculate posttransfusion survival, and it reported 4-year posttransfusion probabilities of survival for patients transfused in 1988-96. 5 Of 695 patients from that study, 5 227 had received transfusion(s) in 1988-90 and had thus been followed until death or for 120 months by the time of the study. Table 1 shows the 10-year survival of these subjects.
The 26.0 percent overall survival is 46.2 percent lower than the 48.3 percent survival calculated for Olmsted County residents transfused in 1981. 2 Of the NYUMC patients, 63.4 percent ( Table 1) had received more than 10 RBC units in the course of 1 year, as compared to 8.6 percent of the Olmsted County residents. 2 Even in the 1990s, probably less than 10 percent of the members of an unselected, transfused, community population receive more than 10 RBC units in the course of 1 year. When the NYUMC (Table 1) and Olmsted County 2 study populations were stratified by transfusion dose, the reduction in survival between the two studies was 14.7 percent for recipients of Յ10 RBC units and 31.0 percent for recipients of more than 10 RBC units. Therefore, if the NYUMC 10-year probabilities of survival were applied to a transfused community population (with 10% of the members of that population receiving more than 10 RBC units in the course of 1 year), a 10-year survival of 40 percent would be calculated for that community population.
For patients transfused in 1993 in two Swedish counties, Tynell et al. 6 reported 1-year probabilities of survival that were 13 percent lower than those reported from Olmsted County, 2 and 40-month probabilities of survival that were 20 percent lower than the Olmsted County figures. For patients transfused in 1994 in northern England, Wells et al. 7 reported 2-and 5-year probabilities of survival that were, respectively, 15 percent and 22 percent lower than the Olmsted County figures. 2 Thus, when data on posttransfusion survival are needed as input for future studies, posttransfusion survival probabilities of 66, 6 60, 7 47, 7 and 40 percent, respectively, at 1, 2, 5, and 10 years posttransfusion can be used until definitive empirical data become available. A population-based study that includes several US counties has to be conducted to generate the information needed for public policy decisions in the future. 
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